Latigo Biotherapeutics, Inc. Common Stock (LTGO) - Total Assets
Based on the latest financial reports, Latigo Biotherapeutics, Inc. Common Stock (LTGO) holds total assets worth $64.76 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see LTGO cash generation efficiency for how efficiently the company converts equity into cash flow.
Latigo Biotherapeutics, Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Latigo Biotherapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Latigo Biotherapeutics, Inc. Common Stoc (LTGO) share price today for real-time trading data and today's change.
Latigo Biotherapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Latigo Biotherapeutics, Inc. Common Stock's total assets of $64.76 Million consist of 97.8% current assets and 2.2% non-current assets. Explore working capital to net assets of Latigo Biotherapeutics, Inc. Common Stoc to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Latigo Biotherapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Latigo Biotherapeutics, Inc. Common Stock's current assets represent 97.8% of total assets in 2025, an increase from 92.6% in 2024.
- Cash Position: Cash and equivalents constituted 92.0% of total assets in 2025, up from 78.4% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Latigo Biotherapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Latigo Biotherapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
USA | $1.08 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
USA | $1.21 Billion |
|
LegoChem Biosciences Inc
KQ:141080
|
Korea | ₩652.93 Billion |
Latigo Biotherapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 3.23 | - |
| Quick Ratio | 1.15 | 3.23 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $7.62 Million | $32.35 Million | - |
Latigo Biotherapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Latigo Biotherapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 14.05 |
| Asset Growth Rate (YoY) | 230.3% |
| Total Assets | $75.52 Million |
| Market Capitalization | $1.06 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Latigo Biotherapeutics, Inc. Common Stock's assets at a significant premium (14.05x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Latigo Biotherapeutics, Inc. Common Stock's assets grew by 230.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Latigo Biotherapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Latigo Biotherapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $75.52 Million | +230.28% |
| 2024-12-31 | $22.86 Million | -- |
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting … Read more